What makes DPharm an extraordinary event is the leadership from all levels of the industry coming together to share their innovation insights with the goal of modernizing 21st century drug development.

NEW YORK

The Conference Forum has announced that the 9th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference will take place on September 17-18, 2018 at the Renaissance Waterfront Hotel in Boston, MA, with a full day dedicated to Mobile in Clinical Trials on September 16.

Dr Scott Gottlieb, 23rd Commissioner of the FDA, has chosen DPharm to deliver his perspective on how to modernize clinical trials in one of the opening keynotes for this year. Tammy Guld, Janssen Clinical Innovation Global Lead, Janssen will lead the event as co-chair, and in a patient advocate opening keynote, Radio City Rockette, Alyssa Epstein will share her patient story as a breast cancer survivor.

As one of DPharm’s R&D innovation leadership keynotes, Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda, will discuss the development of KPIs that support innovation for patient engagement. Joining Dr Plump will be Dr Jessica Scott, Takeda’s Head of R&D Patient Engagement. Delivering a cornerstone presentation on disruptive restoration on internal clinical operations will be Merck’s Dr Mark Travers, VP, Head of GCTO Regions, Monitoring Excellence, Global Operations. Finally, Dr Ülo Palm, SVP, Head, Global Drug Development Operations, Allergan, asks what’s going to revolutionize medical research in a keynote on the implications for Pharma R&D.

Guest keynotes, David Lidsky, Deputy Editor, Fast Company, is joined by Dr Shwen Gwee, Co- Founder, Novartis Biome, and General Manager, Head of Open Innovation, Novartis, in a discussion on Fast Company magazine’s annual innovation report ranking the world’s 50 most innovative companies. Kerry Hicks, the founder of Healthgrades, leads a fireside keynote discussion on transparency and the future of patient expectations with Craig Lipset, Former Head of Clinical Innovation, Pfizer. Providing an out-of-industry perspective on customer engagement, Starbucks’ Robert Mercer, Design Director, Global Digital Products, is joined by Eli Lilly’s Joseph Kim, Senior Advisor, Clinical Operations and Digital Registry, Digital Health Office, Translational Technology & Innovation.

In the first of three Zeitgeist talks, Milind Kamkolkar, Chief Data Officer, Cellarity, joins DPharm to discuss big data and AI for drug development. Arguably, the most credible voice on operationalizing EHR e-source, Meredith Zozus, PhD, Associate Professor and Vice Chair for Academic Programs, University of Arkansas for Medical Sciences’ College of Medicine will speak to this and in particular separating the hype from reality. Dr Zozus is joined in discussion with Michele Cherry, Senior Manager, Client Partner at Pfizer. In a talk on hacking and why it’s important for your clinical trials, Janine Medina, Executive Director, Biohacking Village, covers a subject not typically associated with clinical trial innovation. Joining her in conversation will be Andy Coravos, former entrepreneur-in-residence at the FDA.

“What makes DPharm an extraordinary event is the leadership from all levels of the industry coming together to share their innovation insights with the goal of modernizing 21st century drug development,” said Valerie Bowling, Executive Director, the Conference Forum.

Legendary investor Esther Dyson, Executive Founder, Way to Wellville and Board Member, 23andMe, will be returning as a judge on DPharm Idol, the event’s annual live show featuring a select group of innovators, who present what they believe is a disruptive service or technology that could change clinical trials. DPharm Idol judges include:

  • Sandra Freeman, Associate Director, Global Clinical Operations, Johnson and Johnson
  • Cindy Geoghegan, Cancer Veteran and Patient Advocate
  • Hassan Kadhim, Director, Head of Clinical Trial Business Capabilities, BMS
  • Ülo Palm, MD, PhD, SVP, Head, Global Drug Development Operations, Allergan
  • Chandra Ramanathan, PhD, MBA, Head, East Coast Innovation Center, Bayer, US
  • Jessica Scott, MD, JD, Head of R&D Patient Engagement, Takeda
  • John Varaklis, Head of Global Clinical Operations, Roche Pharmaceutical Research and Early Development (pRED)

With more than 20 pharma companies reporting on specific innovations they have implemented to better deliver new medicines, DPharm 2019 covers the full spectrum of clinical research. This includes virtual trials, digital applications, real-world data, big data management, AI applications, MAPs, EHR eSource operations, patient-centric strategies, new business models, collaborations, technologies and more.

To learn more about the event, please visit DPharm 2019.

About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research.

Powered by WPeMatico